Johnson and Johnson deal enables full funding of Elan’s AIP
The winner of this year’s Mergers and Acquisitions Deal of the Year: Public is the Johnson and Johnson acquisition of Elan Alzheimer’s Immunotherapy Program (AIP) was the largest deal in 2009, will allow Elan to fully fund the AIP programme all the way to commercialisation while strengthening the shareholder base and reducing overall risk.
According to John Given, partner, A&L Goodbody (pictured) who advised on the deal, ‘it is the first time a main market listed Irish company has raised funds by way of a cash box structure and was a highly innovative method of securing the equity investment for Elan in an expeditious manner with lower market risk.’ |